Amgen Stock (AMGN) Opinions on Q1 Earnings Preview

Ahead of its Q1 2026 earnings, Amgen (AMGN) is experiencing increased social media buzz, with analysts projecting a robust full-year EPS of $22.18, and particular attention on the obesity drug MariTide. Insider trading shows more sales than purchases, while congressional trading has a mix of purchases and sales. Analysts maintain positive ratings and price targets, with a median target of $351.0.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin